Rimonabant

Email this page to a friend

Want news about Rimonabant and more e-mailed to you? Click here for free email alerts

Bottom Line's Health Breakthroughs 2007 Bottom Line Health See book keywords and concepts

The other is orlistat (Xenical), and a third medication, rimonabant (Acomplia), showed promising results in a trial, and is currently undergoing FDA review. The international study on rimonabant was led by Jean-Pierre Despres of Laval University in Sainte-Foy, Quebec, Canada, and involved more than 1,000 overweight or obese patients who had untreated high cholesterol The participants were placed on a low-calorie diet and given either daily rimonabant (at doses of 5 or 20 mg) or a placebo. Don't look for a quick fix from the drug store.

Nutrition in the Prevention and Treatment of Disease Ann M. Coulston and Carol J. Boushey See book keywords and concepts

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO_Europe Study. Lancet 365, 1389-1397. 110. Scheen, A., Finer, N., Hollander, P., Jensen, M., Van Gaal, L., and Rio Diabetes study Group. (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 368, 1660-1672. 111. The RIO-North America Study Group. (2006).

If rimonabant achieves FDA approval, it will represent a new class of obesity drugs available for health care providers to manage body weight. rimonabant is approved for use in Europe and Canada, but the FDA has not approved it for use in the United States. F. Risk/Benefit Ratio 1. Selecting Patients for Pharmacotherapy After the degree of obesity has been assessed and the presence of comorbidities determined, the potential risks and benefits of a particular pharmacotherapy should be determined for each patient.

Further evaluation of this type of adverse event and who is at risk will be necessary before the FDA approves this drug for general use. If rimonabant achieves FDA approval, it will represent a new class of obesity drugs available for health care providers to manage body weight. rimonabant is approved for use in Europe and Canada, but the FDA has not approved it for use in the United States. F. Risk/Benefit Ratio 1.

Big Pharma: Exposing the Global Healthcare Agenda Jacky Law See book keywords and concepts

Answers to questions that remain unanswered by tests on rimonabant may come from another source, however. A drug to treat multiple sclerosis and post-operative pain is also in the pipeline and this works in precisely the opposite way, by stimulating a similar set of receptors that rimonabant stunts ('prescription dope', in other words). Data on this drug refers to the same canniboid receptors as rimonabant but the questions asked were very different.

Nutrition in the Prevention and Treatment of Disease Ann M. Coulston and Carol J. Boushey See book keywords and concepts

Sjostrom, L., rimonabant in Obesity-Lipids Study Group. (2005). Effects of rimonabant 129. on metabolic risk factors in overweight patients with dysli-pidemia. N. Engl. J. Med. 353, 2121-2134. 113. Sjostrom, L. V. (1992). Mortality of severely obese subjects. 130. Am. J. Clin. Nutr. 55, 516S-523S. 114. Sturm, R. (2007). Increases in morbid obesity in the USA: 2000-2005. Public Health, doi: 10.1016/j.puhe.2007.01.006. 115. Zhao, Y., and Encinosa, W. (2007). Bariatric surgery utili-zatation and outcomes in 1998 and 2004. Statistical brief#23. 131.

Bottom Line's Health Breakthroughs 2007 Bottom Line Health See book keywords and concepts

We know that rimonabant improves [cardiovascular] risk factors, but we don't know yet if that translates into a reduction in heart disease or death," Yanovski says. "Rimonabant is a little bit different in that it acts not only on the brain but also on other tissues in the body, such as fat cells and those in the gastrointestinal tract," she says. STUDY #3: KEEPING TRACK A third study found that people who get in the habit of weighing themselves every day are more successful at losing weight than those who do not monitor their weight daily.

Big Pharma: Exposing the Global Healthcare Agenda Jacky Law See book keywords and concepts

A drug to treat multiple sclerosis and post-operative pain is also in the pipeline and this works in precisely the opposite way, by stimulating a similar set of receptors that rimonabant stunts ('prescription dope', in other words). Data on this drug refers to the same canniboid receptors as rimonabant but the questions asked were very different. Street sellers of cannabis would probably ask their customers another set of questions again, selling as they do the effects of the drug on the mind rather than on appetite or pain awareness.

Nutrition in the Prevention and Treatment of Disease Ann M. Coulston and Carol J. Boushey See book keywords and concepts

RlMONABANT XX The newly discovered endocannabinoid system and canna-binoid receptor, with their reported roles in the regulation of energy balance and body composition, offer a new target to induce weight loss and improve the metabolism of carbohydrates and lipids. rimonabant, a selective cannabinoid-1 receptor blocker, is the compound closest to achieving future FDA approval. It has been shown in four phase III trials to reduce body weight and improve cardiovascular risk factors in obese patients [109-112]. The most common side effects are nausea, dizziness, arthralgia, and diarrhea.

Effects of rimonabant 129. on metabolic risk factors in overweight patients with dysli-pidemia. N. Engl. J. Med. 353, 2121-2134. 113. Sjostrom, L. V. (1992). Mortality of severely obese subjects. 130. Am. J. Clin. Nutr. 55, 516S-523S. 114. Sturm, R. (2007). Increases in morbid obesity in the USA: 2000-2005. Public Health, doi: 10.1016/j.puhe.2007.01.006. 115. Zhao, Y., and Encinosa, W. (2007). Bariatric surgery utili-zatation and outcomes in 1998 and 2004. Statistical brief#23. 131. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb23.pdf.

Best Choices From the People's Pharmacy Joe Graedon, M.S. and Teresa Graedon, Ph.D. See book keywords and concepts

The claims being made about rimonabant (Acomplia) are extraordinary. It is easy to understand why some people might be eager to try it, even if others are skeptical. The manufacturer, Sanofi-Aventis, is being especially careful to downplay the cosmetic weight-reducing potential of Acomplia. Instead, they are highlighting other benefits, such as the improvement of lipid profiles. In three large clinical trials, Acomplia resulted in promising metabolic improvements.840,841'842 Good HDL cholesterol rose and bad triglycerides dropped. Insulin efficiency improved and blood sugar levels came down.

In addition, investigators þ rimonabant (Acomplia) Acomplia is different from other prescription diet pills because it works on an entirely new mechanism. It blocks brain CB(1) (cannabi-noid 1) receptors that respond to natural marijuana-like compounds. It is more effective than any other medication for weight loss, helping people lose more than 15 pounds over the course of a year. Acomplia also has beneficial effects on good HDL cholesterol, triglycerides, insulin efficiency, blood sugar level, and blood pressure.

Big Pharma: Exposing the Global Healthcare Agenda Jacky Law See book keywords and concepts

The relatively new European drugs conglomerate, Sanofi-Aventis, for example, is developing an obesity drug known generically as rimonabant that exploits knowledge of the 'munchies', a side effect of the recreational drug, cannabis. The modus operandi is to stunt activity of the canniboid receptors, thus reducing appetite. Such receptors are found throughout the body, including in the fat cells, and so far, the trial results have been encouraging. 'Data available so far have shown that the product is effective,' said pharmaceutical journalist Ailis Kane in January 2004.

Data on this drug refers to the same canniboid receptors as rimonabant but the questions asked were very different. Street sellers of cannabis would probably ask their customers another set of questions again, selling as they do the effects of the drug on the mind rather than on appetite or pain awareness. A further avenue of questioning for anti-obesity research is the idea of a vaccine which can lead to lower appetites, thereby apparently making it easier to follow weight-reducing diets.

FAIR USE NOTICE: The research quoted here is provided under the protection of Fair Use provisions and published by the 501(c)3 non-profit Consumer Wellness Center for the purposes of public comment and education. Authors / publishers may submit books for consideration of inclusion here.

TERMS OF USE: Read full terms of use. Citations of text from NaturalPedia must include: 1) Full credit to the original author and book title. 2) Secondary credit to the Natural News Naturalpedia as a research resource and a link to www.NaturalNews.com/np/index.html

This unique compilation of research is copyright (c) 2008 by the non-profit Consumer Wellness Center.

ABOUT THE CREATOR OF NATURALPEDIA: Mike Adams, the creator of this NaturalNews Naturalpedia, is the editor of NaturalNews.com, the internet's top natural health news site, creator of the Honest Food Guide (www.HonestFoodGuide.org), a free downloadable consumer food guide based on natural health principles, author of Grocery Warning, The 7 Laws of Nutrition, Natural Health Solutions, and many other books available at www.TruthPublishing.com, creator of the earth-friendly EcoLEDs company (www.EcoLEDs.com) that manufactures energy-efficient LED lighting products, founder of Arial Software (www.ArialSoftware.com), a permission e-mail technology company, creator of the CounterThink Cartoon series (www.NaturalNews.com/index-cartoons.html) and author of over 1,500 articles, interviews, special reports and reference guides available at www.NaturalNews.com. Adams' personal philosophy and health statistics are available at www.HealthRanger.org.